sofwave treatment sagging skin neck glp-1 Sofwave® for Ozempic™ Face in NYC One single Sofwave treatment on
Description
October 2024 The GLP-1 receptor agonist drug class has revolutionized obesity treatment, and has spurred investment and innovation across the pharmaceutical industry
231 In non-randomized interventions, FIM therapies are associated with BMI reductions of 0.4 to 0.6 kg/m 2
When weight loss occurs gradually, skin has time to contract and adapt to reduced underlying volume
Below 72 hours
Common side effects include gastrointestinal symptoms (nausea, vomiting, diarrhoea)
